Health & Biotech ASX Health Stocks: Clarity Pharma, Island Pharma set to embark on next steps of clinical trials November 7, 2023 Clarity Pharma says 50 patients have been imaged at SABRE trial. Island Pharma granted human research ethics approval for ISLA-101. Race Oncology releases ‘striking’ interim Phase 2 AML trial results November 7, 2023 Special Report: Race Oncology’s latest Phase II study results is giving hope to relapsed or refractory Acute Myeloid Leukaemia (R/R… ADX Energy eyes thicker target areas at Anshof-2 to significantly increase 2P reserves and oil production November 7, 2023 ADX Energy is nearing the spud date of its Anshof-2 well at the Anshof field expecting to both increase proven… ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed November 6, 2023 PYC to take its ADOA drug to human clinical trials. Imugene to progress with Phase 1 MAST (Metastatic Advanced Solid… Aroa maintains FY24 revenue growth forecast at 30pc after strong Q2 November 6, 2023 Soft tissue repair company Aroa Biosurgery has maintained its FY24 product revenue guidance at NZ$72-75 million, representing a 25-30% increase… ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally) November 3, 2023 ASX health stocks have risen this week in line with broader markets as Mach 7 (ASX:M7T) reports record sales in… Data shows Argenica’s drug inhibits another main cause of Alzheimer’s disease November 3, 2023 Special Report: Preclinical data demonstrates Argenica Therapeutics' ARG-007 inhibits main abnormal proteins which cause Alzheimer’s disease. Q+A: Neurotech’s Dr Thomas Duthy on commercialising NTI164 as a treatment for PANDAS/PANS November 3, 2023 Special Report: Neurotech International achieved a key milestone with positive results from its Phase I/II clinical trial into conditions where… ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer’s data November 3, 2023 Market darling Neuren jumps after reporting big growth in sales of DAYBUE. Argenica also jumps on Alzheimer's pre-clinical data. ASX Health Stocks: Island Pharma granted Aussie patent for flavivirus infection drug, ISLA-101 November 2, 2023 Island Pharma received Australian patent grant for antiviral drug, ISLA-101. Chimeric does first patient in its Phase 1B clinical trial. Next» « Previous